Ophthal Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Doctors and the DEA Free full text

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Second Phase III Study Showed Lucentis Improved Vision in Patients with Retinal Vein Occlusion
Genentech, 07/31/09

Genentech, Inc., a wholly–owned member of the Roche Group, announced that the Phase III study CRUISE showed Lucentis improved vision, as measured by the primary endpoint of mean change from baseline in best–corrected visual acuity at six months, in patients with macular edema due to central retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study.

<< Previous
Proteomics of uveal melanomas suggests HSP-27 as a possible...

Next >>
Heterozygous loss of function variants in CYP1B1 predispose to...